NCR Online Journal

X-Linked Retinitis Pigmentosa Market Insights, Epidemiology By DelveInsight

 Breaking News
  • No posts were found

X-Linked Retinitis Pigmentosa Market Insights, Epidemiology By DelveInsight

August 11
22:22 2020
X-Linked Retinitis Pigmentosa Market Insights, Epidemiology By DelveInsight

DelveInsight has launched a new report on X-Linked Retinitis Pigmentosa Market

 

DelveInsight’s “X-Linked Retinitis Pigmentosa (XLRP) Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa (XLRP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The X-Linked Retinitis Pigmentosa (XLRP) market report provides current treatment practices, emerging drugs, X-Linked Retinitis Pigmentosa (XLRP) market share of the individual therapies, current and forecasted X-Linked Retinitis Pigmentosa (XLRP) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current X-Linked Retinitis Pigmentosa (XLRP) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

 

X-linked Retinitis Pigmentosa (XLRP) caused by mutations in the Retinitis Pigmentosa GTPase regulator (RPGR) gene is the most common form of recessive RP. The RPGR gene is located on the X-chromosome; this is why the disease affects men and women in a different way. XLRP affects boys and young men by initial symptoms, such as night blindness and lack of dark adaptation, within the first decade of life. In the second decade, patients usually have a reduced visual field and visual acuity, which later results in complete blindness by the third or fourth decade of life. Female carriers may also be affected with a milder form of the disease with peripheral pigmentary changes in the retina. XLRP often results in total blindness, and there is no specific treatment for this condition.

 

 

 

Request for free sample page: https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-market

 

X-linked Retinitis Pigmentosa Treatment

XLRP is the condition that begins with night blindness leading to permanent blindness. It is an inherited condition and there is no specific treatment for this. Off-label therapies have been observed to provide a positive response in the treatment of patients with XLRP. Photoreceptor function can be potentially preserved by the administration of vitamin A palmitate, lutein, calcium-channel blockers, and docosohexanoic acid, which slow the rate of retinal degeneration. Vitamin A palmitate is used to slow down the rate of retinal degeneration. Also, adult patients with common forms of RP and good general health are recommended to take Vitamin A palmitate under the supervision of healthcare experts. Lutein and/or zeaxanthin (macular pigments from dietary sources), for 6 months, have shown to increase macular pigment in approximately half of the individuals with RP, without a change in central vision.

 

X-linked Retinitis Pigmentosa Market

Mutations in the RPGR gene can be associated with a rod-cone or cone-rod dystrophy phenotype. It is initially identified with difficulties in scotopic visual function, where there is a predominant loss of rod photoreceptors. Also, there is peripheral vision deteriorates, resulting in visual field narrowing on perimetry findings. In some cases, patients also present early cone involvement and correspondingly impaired central visual acuity during early stages of the disease.

 

X-linked Retinitis Pigmentosa Report Scope

  • The report covers the descriptive overview of X-Linked Retinitis Pigmentosa (XLRP), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the X-Linked Retinitis Pigmentosa (XLRP) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for X-Linked Retinitis Pigmentosa (XLRP) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of X-Linked Retinitis Pigmentosa (XLRP) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global X-Linked Retinitis Pigmentosa (XLRP) market

 

Download free sample page: – https://www.delveinsight.com/sample-request/x-linked-retinitis-pigmentosa-market

 

Table of content

1. Key Insights

2. Executive Summary of X-Linked Retinitis Pigmentosa (XLRP)

3. Competitive Intelligence Analysis for X-Linked Retinitis Pigmentosa (XLRP)

4. X-Linked Retinitis Pigmentosa (XLRP): Market Overview at a Glance

5. X-Linked Retinitis Pigmentosa (XLRP): Disease Background and Overview

6. Patient Journey

7. X-Linked Retinitis Pigmentosa (XLRP) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of X-Linked Retinitis Pigmentosa (XLRP) Treatment

11. Marketed Products

12. Emerging Therapies

13. X-Linked Retinitis Pigmentosa (XLRP): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of X-Linked Retinitis Pigmentosa (XLRP)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the X-Linked Retinitis Pigmentosa (XLRP) market
  • To understand the future market competition in the X-Linked Retinitis Pigmentosa (XLRP) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for X-Linked Retinitis Pigmentosa (XLRP) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for X-Linked Retinitis Pigmentosa (XLRP) market
  • To understand the future market competition in the X-Linked Retinitis Pigmentosa (XLRP) market

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

 

Contact Us

Shruti Thakur
[email protected]
+91-9650213330

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles